Pasithea Therapeutics wins Nasdaq extension to regain $1 minimum bid compliance
KTTA•Reverse stock split flagged as a possible remedy
Management flagged a potential reverse stock split as a compliance measure.
Nasdaq grants extension on minimum bid price rule
Pasithea Therapeutics received a Nasdaq notice of non-compliance with the $1 minimum bid price rule.
Nasdaq granted a 180-day extension to regain compliance, setting a new deadline of Feb. 16, 2027.
Failure to meet the requirement by the deadline could trigger a delisting notice, with an option to appeal to a hearings panel.
